Menopause hormone treatment after cancer

References

• Abubakar M, Chang-Claude J, Ali HR, et al. Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. Int J Cancer. 2018;143(4):746–757.
   PubMed Web of Science ®Google Scholar
• Ellingjord-Dale M, Vos L, Tretli S, et al. Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. Breast Cancer Res. 2017;19(1):10.
   PubMedGoogle Scholar
• Salagame U, Banks E, O’Connell DL, et al. Menopausal hormone therapy use and breast cancer risk by receptor subtypes: results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study. PLoS One. 2018;13(11):e0205034.
   PubMed Web of Science ®Google Scholar
• Sisti JS, Collins LC, Beck AH, et al. Reproductive risk factors in relation to molecular subtypes of breast cancer: results from the nurses’ health studies. Int J Cancer. 2016;138(10):2346–2356.
   PubMed Web of Science ®Google Scholar
• Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014;144(1):1–10.
   PubMed Web of Science ®Google Scholar
• Morra A, Jung AY, Behrens S, et al. Breast cancer risk factors and survival by tumor subtype: pooled analyses from the breast cancer association consortium. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2021;30(4):623–642.
   Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647–3661.
   PubMed Web of Science ®Google Scholar
• Rachner TD, Coleman R, Hadji P, et al. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018;6(11):901–910.
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017;28(3):487–496.
   PubMed Web of Science ®Google Scholar
• Porter C, Azam TU, Mohananey D, et al. Permissive cardiotoxicity: the clinical crucible of cardio-oncology. JACC CardioOncol. 2022;4(3):302–312.
   PubMedGoogle Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer. 2002;95(9):1817–1826.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475–482.
   PubMedGoogle Scholar
• Angioli R, Luvero D, Armento G, et al. Hormone replacement therapy in cancer survivors: Utopia? Crit Rev Oncol Hematol. 2018;124:51–60.
   PubMed Web of Science ®Google Scholar
• von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005;97(7):533–535.
   PubMedGoogle Scholar
• Holmberg L, Anderson H; HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer–is it safe?), a randomised comparison: trial stopped. Lancet Lond Engl. 2004;363(9407):453–455.
   PubMed Web of Science ®Google Scholar
• Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013;49(1):52–59.
   PubMed Web of Science ®Google Scholar
• Marsden J, Whitehead M, A’Hern R, et al. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril. 2000;73(2):292–299.
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10(2):135–146.
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76(1–5):231–238.
   PubMed Web of Science ®Google Scholar
• Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269–275.
   PubMed Web of Science ®Google Scholar
• Ugras SK, Layeequr Rahman R. Hormone replacement therapy after breast cancer: yes, no or maybe? Mol Cell Endocrinol. 2021;525:111180.
   PubMed Web of Science ®Google Scholar
• Mruthyunjayappa S, Zhang K, Zhang L, et al. Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes. Hum Pathol. 2019;92:1–9.
   PubMed Web of Science ®Google Scholar
• van Barele M, Heemskerk-Gerritsen BAM, Louwers YV, et al. Estrogens and progestogens in triple negative breast cancer: do they harm? Cancers. 2021;13(11):2506.
   PubMed Web of Science ®Google Scholar
• “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause N Y N. 2022;29(7):767–94.
   PubMed Web of Science ®Google Scholar
• Mendoza N, Ramírez I, de la Viuda E, et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65–85.
   PubMed Web of Science ®Google Scholar
• Shufelt C, Bairey Merz CN, Pettinger MB, et al. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. Menopause. 2018;25(9):985–991.
   PubMed Web of Science ®Google Scholar
• Bhupathiraju SN, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause N Y N. 2019;26(6):603–610.
   Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol. 2006;108(6):1354–1360.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018;25(6):596–608.
   PubMed Web of Science ®Google Scholar
• Rees M, Angioli R, Coleman RL, et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020;134:56–61.
   PubMed Web of Science ®Google Scholar
• Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol. 2020;31(6):674–696.
   PubMed Web of Science ®Google Scholar
• Cold S, Cold F, Jensen MB, et al. Systemic or vaginal hormone therapy After early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347–1354.
   PubMedGoogle Scholar
• Barton DL, Shuster LT, Dockter T, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (alliance). Support Care Cancer. 2018;26(4):1335–1343.
   PubMed Web of Science ®Google Scholar
• Gernier F, Ahmed-Lecheheb D, Pautier P, et al. Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors. BMC Cancer. 2021;21(1):1147.
   PubMed Web of Science ®Google Scholar
• Gernier F, Gompel A, Rousset-Jablonski C, et al. Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study. Gynecol Oncol. 2021;163(3):598–604.
   PubMed Web of Science ®Google Scholar
• Rousset-Jablonski C, Selle F, Adda-Herzog E, et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. Eur J Cancer Oxf Engl 1990. 2019;116:35–44.
   PubMed Web of Science ®Google Scholar
• Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer. 1999;86(6):1013–1018.
   PubMed Web of Science ®Google Scholar
• Li L, Pan Z, Gao K, et al. Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncol Lett. 2012;3(1):244–249.
   PubMed Web of Science ®Google Scholar
• Eeles RA, Morden JP, Gore M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin Oncol. 2015;33(35):4138–4144.
   PubMed Web of Science ®Google Scholar
• Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol. 2015;139(2):355–362.
   PubMed Web of Science ®Google Scholar
• Sinno AK, Pinkerton J, Febbraro T, et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: a Society of Gynecologic Oncology (SGO) clinical practice statement: this practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol. 2020;157(2):303–306.
   PubMed Web of Science ®Google Scholar
• Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(4):587–592.
   PubMed Web of Science ®Google Scholar
• Maxwell GL, Tian C, Risinger JI, et al. Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy? Cancer. 2008;113(6):1431–1437.
   PubMed Web of Science ®Google Scholar
• Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;5(5):CD008830.
   PubMedGoogle Scholar
• Londero AP, Parisi N, Tassi A, et al. Hormone replacement therapy in endometrial cancer survivors: a meta-analysis. JCM. 2021;10(14):3165.
   Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–e203.
   PubMed Web of Science ®Google Scholar
• Abdalla E, Troy R, Fall S, et al. Racial differences in 5-year relative survival rates of cervical cancer by stage at diagnosis, between African American (black) and white women, living in the state of Alabama, USA. BMC Cancer. 2020;20(1):830.
   PubMed Web of Science ®Google Scholar
• Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol. 1987;26(2):169–177.
   PubMed Web of Science ®Google Scholar
• Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch. 2019;475(5):537–549.
   PubMed Web of Science ®Google Scholar
• Stolnicu S, Hoang L, Chiu D, et al. Clinical outcomes of HPV-associated and unassociated endocervical adenocarcinomas categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol. 2019;43(4):466–474.
   PubMed Web of Science ®Google Scholar
• Lacey JV, Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol. 2000;77(1):149–154.
   PubMed Web of Science ®Google Scholar
• Kostov S, Kornovski Y, Ivanova V, et al. New aspects of sarcomas of uterine corpus-a brief narrative review. Clin Pract. 2021;11(4):878–900.
   PubMed Web of Science ®Google Scholar
• Huang X, Peng P. Hormone therapy reduces recurrence in stage II-IV uterine low-grade endometrial stromal sarcomas: a retrospective cohort study. Front Oncol. 2022;12:922757.
   PubMed Web of Science ®Google Scholar
• Nasioudis D, Ko EM, Kolovos G, et al. Ovarian preservation for low-grade endometrial stromal sarcoma: a systematic review of the literature and meta-analysis. Int J Gynecol Cancer. 2019;29(1):126–132.
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Lyytinen HK, Pukkala E, et al. Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas. Gynecol Oncol. 2011;122(2):260–263.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis. Int J Clin Oncol. 2020;25(5):885–891.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Wakelee H, Pettinger M, et al. Estrogen plus progestin and lung cancer: follow-up of the women’s health initiative randomized trial. Clin Lung Cancer. 2016;17(1):10–17.e1.
   PubMed Web of Science ®Google Scholar
• Li W, Lin X, Wang R, et al. Hormone therapy and lung cancer mortality in women: systematic review and meta-analysis. Steroids. 2017;118:47–54.
   PubMed Web of Science ®Google Scholar
• Daugherty SE, Lacey JV, Pfeiffer RM, et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer. 2013;133(2):462–472.
   PubMed Web of Science ®Google Scholar
• Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: an overestimated risk? Eur J Cancer. 2017;84:60–68.
   PubMed Web of Science ®Google Scholar